Eli Lilly has announced its acquisition of Kelonia Therapeutics for up to $7 billion, with an upfront payment of $3.25 billion and additional contingent payments tied to clinical and regulatory milestones. This strategic move, expected to close in the second half of 2026, positions Lilly to leverage Kelonia’s innovative in vivo CAR-T technology, which reprograms patients’ T-cells to target cancer directly within the body, offering a more streamlined alternative to traditional ex vivo methods.
The acquisition underscores Lilly’s ambition to diversify its portfolio beyond its well-known GLP-1 drugs for obesity and diabetes. With the CAR-T market growing—Johnson & Johnson’s Carvykti generated nearly $1.9 billion in sales last year—Lilly aims to capitalize on the convenience of one-time infusion therapies, potentially expanding its reach in hematology and solid tumors. This shift towards later-stage acquisitions reflects a strategic pivot to balance high-volume early-stage deals with opportunities that offer more clinical validation.
Market professionals should note that Lilly’s aggressive acquisition strategy not only enhances its oncology pipeline but also signals a commitment to broadening its therapeutic focus, which could impact its stock performance and investor sentiment in the coming years.
Source: cnbc.com